文献速递炎症性肠病

Etrasimod 在中重度溃疡性结肠炎二期随机试验中的疗效与安全性

Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis.
PubMed 文献 · Gastroenterology · 2019-11-09

这项二期、双盲、平行组研究纳入中重度活动性溃疡性结肠炎成人患者,随机接受每日一次 etrasimod 1 mg、2 mg 或安慰剂治疗 12 周。结果显示 etrasimod 2 mg 组在改良 Mayo 评分改善和内镜改善方面均显著优于安慰剂,大多数不良事件为轻中度。

要点

  • 3 例患者出现一过性无症状低度房室传导阻滞,均在 etrasimod 暴露前已有房室传导阻滞证据。

核心结论

  • 在中重度活动性溃疡性结肠炎患者中,etrasimod 2 mg 在产生临床和内镜改善方面比安慰剂更有效。
  • 研究支持进一步开展临床开发。

研究设计与样本

  • 成人门诊患者改良 Mayo 评分4-9、内镜子评分≥2、直肠出血子评分≥1,随机接受每日一次 etrasimod 1 mg(n=52)、2 mg(n=50)或安慰剂(n=54)治疗12周。
  • 主要终点为第12周改良 Mayo 评分较基线的平均改善增加。

主要发现

  • 第12周 etrasimod 2 mg 组达到主要和所有次要终点。
  • 大多数不良事件为轻至中度;3 例患者出现一过性、无症状、低度房室传导阻滞并自行缓解,均在 etrasimod 暴露前已有房室传导阻滞证据。

关键数值与推荐

  • 主要终点:改良 Mayo 评分较基线至第12周的平均改善增加。
  • 次要终点包括第12周内镜改善(子评分≤1)的患者比例。
  • 探索性终点包括临床缓解,但研究仅对主要终点有统计效力。

临床怎么用

  • 对于中重度活动性溃疡性结肠炎,etrasimod 2 mg 每日一次可能改善临床和内镜结局。
  • 治疗前需关注房室传导阻滞证据,治疗中监测相关不良事件。

局限性

  • 研究为二期概念验证试验,仅对主要终点有统计效力。
  • 探索性终点(包括临床缓解)的结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Etrasimod (APD334) is an oral, selective sphingosine 1-phosphate receptor modulator in development for immune-mediated inflammatory disorders. We assessed the efficacy and safety of etrasimod in patients with moderately to severely active ulcerative colitis (UC). METHODS: In a phase 2, proof-of-concept, double-blind, parallel-group study, adult outpatients with modified Mayo Clinic scores (MCSs) (stool frequency, rectal bleeding, and endoscopy findings) of 4-9, endoscopic subscores of 2 or more, and rectal bleeding subscores of 1 or more were randomly assigned to groups given once-daily etrasimod 1 mg (n = 52), etrasimod 2 mg (n = 50), or placebo (n = 54) for 12 weeks. The study was performed from October 15, 2015, through February 14, 2018, at 87 centers in 17 countries. The primary endpoint was an increase in the mean improvement in modified MCS from baseline to week 12. Secondary endpoints included the proportion of patients with endoscopic improvement (subscores of 1 or less) from baseline to week 12. Exploratory endpoints, including clinical remission, are reported in the article, although the study was statistically powered to draw conclusions only on the primary endpoint. RESULTS: At week 12, the etrasimod 2 mg group met the primary and all secondary endpoints. Etrasimod 2 mg led to a significantly greater increase in mean improvement in modified MCS from baseline than placebo (difference from placebo, 0.99 points; 90% confidence interval, 0.30-1.68; P = .009), and etrasimod 1 mg led to an increase in mean improvement from baseline in modified MCS of 0.43 points more than placebo (90% confidence interval, reduction of 0.24 to increase of 1.11; nominal P = .15). Endoscopic improvement occurred in 41.8% of patients receiving etrasimod 2 mg vs 17.8% receiving placebo (P = .003). Most adverse events were mild to moderate. Three patients had a transient, asymptomatic, low-grade atrioventricular block that resolved spontaneously all patients had evidence of atrioventricular block before etrasimod exposure. CONCLUSIONS: In patients with moderately to severely active ulcerative colitis, etrasimod 2 mg was more effective than placebo in producing clinical and endoscopic improvements. Further clinical development is warranted. Clinicaltrials.gov, Number: NCT02447302.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Sandborn WJ, Peyrin-Biroulet L, Zhang J, et al. Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2019. PMID: 31711921. doi:10.1053/j.gastro.2019.10.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。